RESUMEN
Harmful algal blooms plague bodies of freshwater globally. These blooms are often composed of outgrowths of cyanobacteria capable of producing the heptapeptide Microcystin-LR (MC-LR) which is a well-known hepatotoxin. Recently, MC-LR has been detected in aerosols generated from lake water. However, the risk for human health effects due to MC-LR inhalation exposure have not been extensively investigated. In this study, we exposed a fully differentiated 3D human airway epithelium derived from 14 healthy donors to MC-LR-containing aerosol once a day for 3 days. Concentrations of MC-LR ranged from 100 pM to 1 µM. Although there were little to no detrimental alterations in measures of the airway epithelial function (i.e. cell survival, tissue integrity, mucociliary clearance, or cilia beating frequency), a distinct shift in the transcriptional activity was found. Genes related to inflammation were found to be upregulated such as C-C motif chemokine 5 (CCL5; log2FC = 0.57, p = 0.03) and C-C chemokine receptor type 7 (CCR7; log2FC = 0.84, p = 0.03). Functionally, conditioned media from MC-LR exposed airway epithelium was also found to have significant chemo-attractive properties for primary human neutrophils. Additionally, increases were found in the concentration of secreted chemokine proteins in the conditioned media such as CCL1 (log2FC = 5.07, p = 0.0001) and CCL5 (log2FC = 1.02, p = 0.046). These results suggest that MC-LR exposure to the human airway epithelium is capable of inducing an inflammatory response that may potentiate acute or chronic disease.
Asunto(s)
Microcistinas , Agua , Aerosoles/toxicidad , Medios de Cultivo Condicionados , Epitelio , Humanos , Toxinas Marinas , Microcistinas/toxicidad , Receptores CCR7RESUMEN
The prolactin regulatory element-binding protein (PREB) is a transcriptional factor that regulates prolactin (PRL) promoter activity in the anterior pituitary. Prolactinomas are the most common pituitary tumors. Administration of cabergoline, a selective dopamine D2-receptor agonist, has become the initial therapy of choice for most patients with prolactinomas. Although activation of the D2 receptor results in the inhibition of PRL synthesis, the details of the underlying mechanisms remain unknown. Samples of ten prolactinomas and ten nonfunctioning pituitary adenomas were analyzed by immunohistochemistry to detect the expression of PREB. The effect of cabergoline on PREB expression was assessed by western blotting and real-time polymerase chain reaction (PCR) analysis. Reporter gene analysis of PRL was employed to examine the role of PREB on cabergoline-induced suppression of PRL transcription. Immunohistochemical analysis revealed strong positive PREB expression in the prolactinoma tissue, but extremely weak or undetected expression in the nonfunctioning pituitary tumor tissue. Western blots probed with a PREB-specific antiserum revealed that the relative abundance of the PREB protein in the GH3 cells decreased in a dose-dependent manner in response to cabergoline treatment, as did the relative abundance of PREB mRNA. Although cabergoline inhibited the activity of the PRL promoter, mutation of PREB-binding site within the promoter abrogated the ability of cabergoline to inhibit the PRL promoter activity. We have demonstrated that PREB is expressed in prolactinomas and that the suppression of PRL expression by cabergoline requires the transcriptional factor PREB.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Ergolinas/farmacología , Factores de Intercambio de Guanina Nucleótido/metabolismo , Prolactina/genética , Factores de Transcripción/metabolismo , Cabergolina , Línea Celular Tumoral , Humanos , Prolactinoma/metabolismo , Prolactinoma/patología , Regiones Promotoras Genéticas/genética , Transcripción Genética/efectos de los fármacosRESUMEN
OBJECTIVE: We investigated early postoperative hemodynamic and metabolic values using positron emission tomography (PET) scanning in subarachnoid hemorrhage (SAH) patients treated with clipping or coiling, and evaluated usefulness of PET studies in predicting late ischemic events and neurological outcome in SAH patients. METHODS: We examined 14 SAH patients treated with neurosurgical clipping (CLIP group) and 16 patients treated with endovascular coiling (COIL group). Cerebral blood flow (CBF), cerebral metabolic rate for oxygen (CMRO2), and oxygen extraction fraction (OEF) were determined using 15O-PET scanning about 8.5 days after SAH. RESULTS: 1) Mean regional CBF (rCBF) in the middle cerebral artery (MCA) territory was significantly higher in CLIP group compared with COIL group; regional CMRO2 (rCMRO2) and regional OEF (rOEF) were also higher. Four clipped patients showed true hyperemia in the MCA territory; none of the coiled patients showed hyperemia. 2) Surgical intervention significantly decreased mean rCMRO2 and rOEF in the operated frontal lobe compared with the unoperated side. 3) Nine of 30 patients (40%) developed subsequent clinical vasospasm after SAH. Significant differences between the spasm group and non-spasm group were not observed in the MCA territory before vasospasm. CONCLUSION: A wide range of cerebral perfusion patterns including hyperemia were found in the CLIP group. Surgical manipulation of the brain significantly reduced oxygen metabolism in the operated frontal lobe. PET data alone may not have independent prognostic value for detecting delayed cerebral ischemia or in predicting neurological outcome.
Asunto(s)
Circulación Cerebrovascular/fisiología , Tomografía de Emisión de Positrones/métodos , Hemorragia Subaracnoidea/diagnóstico por imagen , Hemorragia Subaracnoidea/fisiopatología , Instrumentos Quirúrgicos/clasificación , Adulto , Anciano , Angiografía , Encéfalo/diagnóstico por imagen , Encéfalo/patología , Encéfalo/fisiopatología , Encéfalo/cirugía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Flujo Sanguíneo Regional/fisiología , Hemorragia Subaracnoidea/patología , Hemorragia Subaracnoidea/cirugía , Ventriculostomía/métodosRESUMEN
In this study, we examine 3CB2 expression, a marker of radial glia, after intracerebral hemorrhage (ICH). Adult male Sprague-Dawley rats received an intracaudate injection of 100 microL autologous whole blood. Animals were sacrificed, and 3CB2 expression was quantified on Western blot. Single and double labeled immunohistochemistry was used to identify which cells express 3CB2. Neurobehavioral examinations (forelimb placing test) were perfomed as an evaluation of function. By Western blot, 3CB2 was strongly expressed at day 3 and expression persisted for at least 1 month. By immunohistochemistry, 3CB2 immunoreactivity was present in large numbers of astrocytes surrounding the hematoma at day 3 after ICH. At 1 month later, 3CB2 immunoreactivity was co-localized with a neuronal marker (TUC-4). Neurobehavioral function in the 1 month after ICH group was significantly improved compared with that of 3 days after ICH. The ICH-induced 3CB2 expression in astrocytes may reflect an early response of these cells to injury, while the delayed expression in neurons might be a part of the adaptative response to injury, perhaps leading to recovery of neurobehavioral function.
Asunto(s)
Hemorragia Cerebral/metabolismo , Hemorragia Cerebral/patología , Regulación de la Expresión Génica/fisiología , Tubulina (Proteína)/metabolismo , Análisis de Varianza , Animales , Hemorragia Cerebral/etiología , Modelos Animales de Enfermedad , Miembro Anterior/fisiopatología , Proteína Ácida Fibrilar de la Glía/metabolismo , Masculino , Proteínas del Tejido Nervioso/metabolismo , Examen Neurológico , Ratas , Ratas Sprague-Dawley , Recuperación de la Función , Factores de TiempoRESUMEN
Stenting for stenosis of the proximal vertebral artery (VA) is commonly performed via a femoral approach. However, iliofemoral occlusive disease such as arteriosclerosis obliterans sometimes prevents safe transfemoral access. In certain situations where both femoral access and ipsilateral brachial access are difficult because of a concomitant vascular diseases or particular anatomic setting, a contralateral brachial approach using the brachiobrachial pull-through technique may allow efficient and accurate stenting. A case of VA origin symptomatic stenosis successfully treated with stenting using the new pull-through technique from the contralateral brachial artery to the brachial artery on the affected side is described.
Asunto(s)
Angioplastia de Balón/métodos , Arteria Braquial , Stents , Insuficiencia Vertebrobasilar/terapia , Anciano , Arteria Braquial/patología , Angiografía Cerebral , Humanos , Claudicación Intermitente/complicaciones , Claudicación Intermitente/diagnóstico por imagen , Claudicación Intermitente/terapia , Angiografía por Resonancia Magnética , Masculino , Insuficiencia Vertebrobasilar/complicaciones , Insuficiencia Vertebrobasilar/diagnósticoRESUMEN
Recent studies revealed that animal toxins with unrelated biological functions often possess a similar architecture. To tentatively understand the evolutionary mechanisms that may govern this principle of functional prodigality associated with a structural economy, two complementary approaches were considered. One of them consisted of investigating the rates of mutations that occur in cDNAs and/or genes that encode a variety of toxins with the same fold. This approach was largely adopted with phospholipases A2 from Viperidae and to a lesser extent with three-fingered toxins from Elapidae and Hydrophiidae. Another approach consisted of investigating how a given fold can accommodate distinct functional topographies. Thus, a number of topologies by which three-fingered toxins exert distinct functions were investigated either by making chemical modifications and/or mutational analyses or by studying the three-dimensional structure of toxin-target complexes. This review shows that, although the two approaches are different, they commonly indicate that most if not all the surface of a snake toxin fold undergoes natural engineering, which may be associated with an accelerated rate of evolution. The biochemical process by which this phenomenon occurs remains unknown.
Asunto(s)
Evolución Molecular , Venenos de Serpiente , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Datos de Secuencia Molecular , SerpientesRESUMEN
Metalloproteinases, myosinase I and myosinase II, that hydrolyze the heavy chain of myosin, were purified from squid mantle muscle. Myosinase I does not hydrolyze other muscle proteins, casein, haemoglobin, or MCA-substrates, while II hydrolyzes tropomyosin. Both myosinase I and myosinase II gave a single protein band on SDS-PAGE with a molecular mass of 16 and 20 kDa, respectively. Their activities were inhibited by EDTA and 1,10-phenanthroline, and II was also inhibited by EGTA. They could be reactivated with some divalent cations, I was especially reactivated with Co2+ and II especially with Zn2+. The optimum pH of both activities was 7.0; the optimum temperature for both was 40 degrees C. Myosinase I hydrolyzes myosin heavy chains to produce 130 and 90 kDa fragments. The N-terminal amino-acid sequence of the 90 kDa fragment indicates that myosinase I splits the myosin heavy chain between Ala-1161 and Thr-1162 in subfragment 2. Myosinase II hydrolyzes myosin heavy chain to produce 158 and 65 kDa fragments, and it splits between Glu-1381 and Thr-1382 in LMM. Myosinases I and II are most likely related to the metabolism of myosin in vivo.
Asunto(s)
Decapodiformes/enzimología , Metaloendopeptidasas/aislamiento & purificación , Músculos/enzimología , Secuencia de Aminoácidos , Animales , Cationes Bivalentes , Pollos , Concentración de Iones de Hidrógeno , Metaloendopeptidasas/química , Datos de Secuencia Molecular , Peso Molecular , Miosinas/metabolismo , Conejos , Especificidad por Sustrato , TemperaturaRESUMEN
Tumor cells become sensitive to the inert prodrug cyclophosphamide (CPA) after transfer of the gene encoding cytochrome P450 2B1. This enzyme activates CPA into 4-hydroxycyclophosphamide, which ultimately degrades into acrolein and phosphoramide mustard, the anticancer and DNA-alkylating metabolite. It is imperative that any prodrug-activating gene therapy strategy against cancer possess the capacity to affect the proliferation of tumor cells even when they do not express the transgene (bystander effect), because current methodologies cannot achieve gene transduction in all tumor cells. Prodrug-activating gene therapy schemes described to date exhibit a bystander effect that is not mediated by conditioned medium in culture and may depend on cell contact. In contrast, we find that CPA-sensitized, P450-expressing C6 glioma cells (C6-P450) transfer cytotoxicity to nonexpressing cells by releasing diffusible metabolites through the medium. A 3-h exposure to the prodrug is necessary and sufficient to achieve killing of the transfected cells, and medium conditioned by these cells can kill untransfected cells with similar potency. This bystander effect occurs in the presence of CPA even when only 10% of cells in culture express the P450 2B1 gene, and it is not reproduced by cells that have been irradiated. In an animal model of intracerebral brain tumors, expression of the P450 2B1 gene within the neoplastic cells enhanced significantly the antitumor effect of CPA, even when it was administered systemically. This study shows that CPA/P450 2B1 gene therapy represents a novel tumor-killing strategy that displays an expanded range of cytotoxic action both spatially and temporally within tumor cells and significantly potentiates the anticancer action of CPA when administered i.v.
Asunto(s)
Antineoplásicos Alquilantes/farmacología , Ciclofosfamida/farmacología , Citocromo P-450 CYP2B1/genética , Terapia Genética/métodos , Profármacos/farmacología , Animales , División Celular , Medios de Cultivo Condicionados/farmacología , Citocromo P-450 CYP2B1/metabolismo , Expresión Génica , Ratas , Ratas Endogámicas F344 , Células Tumorales Cultivadas , Ensayo de Tumor de Célula MadreRESUMEN
p27Kip1 is a cyclin-dependent kinase inhibitor that negatively regulates cell proliferation by mediating cell cycle arrest in G1. This study was undertaken to assess the prognostic value of p27Kip1 for astrocytomas. Tissue samples from 130 astrocytomas (WHO grade 1, 5 cases; grade 2, 23 cases; grade 3, 64 cases; grade 4, 38 cases), including 92 primary and 38 recurrent tumors, were examined immunohistochemically for Ki-67 and p27Kip1 expression. Patient charts were reviewed for clinical presentation, and survival was followed. The p27Kip1 labeling index (LI) ranged from 2.3 to 98.4%, with a mean value of 47.5% (+/-23.4%). The p27Kip1 LI decreased with increasing tumor grade but did not correlate with other parameters. There was no correlation between Ki-67 LI and p27Kip1 LI. For patients with primary astrocytomas, the 50% survival times of those with low p27Kip1 LI (<50%) and those with high p27Kip1 LI (> or =50%) were 17.1 and 69.6 months, respectively. For patients with high-grade tumors, the 50% survival times were 13.1 months for those with low p27Kip1 LI and 33.7 months for those with high LI. On multivariate analysis, p27Kip1 was one of the most significant prognostic factors, indicating that low p27Kip1 LI was associated with poor prognosis (primary, risk ratio = 2.5, P = 0.0023; high-grade, risk ratio = 2.2; P = 0.0139). The expression of p27Kip1 was inversely related to tumor grade and positively related to favorable outcome of patients with astrocytoma, suggesting that p27Kip1 may be a candidate for prognostic factor for this tumor.
Asunto(s)
Astrocitoma/metabolismo , Biomarcadores de Tumor/biosíntesis , Neoplasias Encefálicas/metabolismo , Proteínas de Ciclo Celular , Ciclo Celular/fisiología , Proteínas Asociadas a Microtúbulos/biosíntesis , Proteínas Supresoras de Tumor , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Astrocitoma/mortalidad , Astrocitoma/patología , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Niño , Preescolar , Inhibidor p27 de las Quinasas Dependientes de la Ciclina , Femenino , Humanos , Lactante , Recién Nacido , Antígeno Ki-67/biosíntesis , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Tasa de SupervivenciaRESUMEN
The identification of transgenes with antitumor activity is critical to the development of gene therapy of cancer. Retrovirus-mediated transfer of the Escherichia coli gpt gene into rat C6 glioma cells without subsequent selection still inhibited the proliferation of this mixed polyclonal population upon addition of the prodrug, 6-thioxanthine, with an ID50 of 4.1 microM, whereas parental C6 cells were not affected at a concentration of 500 microM. In a time-course assay, effects of the prodrug on the mixed polyclonal cell proliferation required at least 10 days of exposure. In mixed co-cultures, a bystander effect was not present over the first 4 days of prodrug exposure, but required trypsinization of the co-cultures and replating at lower densities. This "modified" bystander assay thus revealed a 50% decrease in C6 cell proliferation, even when the initial ratio of gpt-expressing to parental C6 cells was as low as 1:19. In a nude mouse model of subcutaneous tumors, co-grafts of C6 glioma and gpt-retrovirus producer cells displayed retarded growth upon exposure to 6-thioxanthine (6-TX). In a nude mouse model of intracerebral tumors, grafting of the gpt-retrovirus producer cells leads to an 80% reduction in intracerebral tumor volumes after 6-TX treatment. This reduction results in a 28% increase in the mean time of survival of animals that harbor intracerebral tumors (p < 0.0005). These antitumor effects indicate that the gpt/6-TX enzyme/prodrug pair is a promising alternative to the thymidine kinase gene and ganciclovir combination in the gene therapy of cancer.
Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/terapia , Escherichia coli/enzimología , Terapia Genética , Glioma/terapia , Hipoxantina Fosforribosiltransferasa/metabolismo , Profármacos/uso terapéutico , Xantinas/uso terapéutico , Animales , Antimetabolitos Antineoplásicos/toxicidad , Neoplasias Encefálicas/tratamiento farmacológico , Modelos Animales de Enfermedad , Escherichia coli/genética , Estudios de Evaluación como Asunto , Técnicas de Transferencia de Gen , Glioma/tratamiento farmacológico , Hipoxantina Fosforribosiltransferasa/genética , Ratones , Ratones Desnudos , Células Tumorales Cultivadas , Xantinas/toxicidadRESUMEN
Three vectors derived from retrovirus, herpes simplex virus type 1 (HSV), and adenovirus were compared in cultured rat 9L gliosarcoma cells for gene transfer efficiency and in a 9L rat brain tumor model for histologic pattern and distribution of foreign gene delivery, as well as for associated tumor necrosis and inflammation. At a multiplicity of infection of 1, in vitro transfer of a foreign gene (lacZ from Escherichia coli) into cells was more efficient with either the replication-defective retrovirus vector or the replication-conditional thymidine kinase (TK)-deficient HSV vector than with the replication-defective adenovirus vector. In vivo, stereotactic injections of each vector into rat brain tumors revealed three main histopathologic findings: (i) retrovirus and HSV vector-mediated gene transfer was relatively selective for cells within the tumor, whereas adenovirus vector-mediated gene transfer occurred into several types of endogenous neural cells, as well as into cells within the tumor; (ii) gene transfer to multiple infiltrating tumor deposits without apparent gene transfer to intervening normal brain tissue occurred uniquely in one animal inoculated with the HSV vector, and (iii) extensive necrosis and selective inflammation in the tumor were evident with the HSV vector, whereas there was minimal evidence of tumor necrosis and inflammation with either the retrovirus or adenovirus vectors.
Asunto(s)
Adenovirus Humanos/genética , Neoplasias Encefálicas/terapia , Vectores Genéticos , Gliosarcoma/terapia , Proteínas Recombinantes de Fusión/biosíntesis , Retroviridae/genética , Simplexvirus/genética , Animales , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Gliosarcoma/genética , Gliosarcoma/patología , Inflamación , Masculino , Necrosis , Células Madre Neoplásicas/metabolismo , Células Madre Neoplásicas/microbiología , Neuroglía/metabolismo , Neuroglía/microbiología , Neuronas/metabolismo , Neuronas/microbiología , Ratas , Ratas Endogámicas F344 , Proteínas Recombinantes de Fusión/genética , Células Tumorales CultivadasRESUMEN
Transduction of the cytosine deaminase (CD) gene into tumor cells followed by administration of 5-fluorocytosine (5-FC), called 5-FC/CD gene therapy, was created as suicide gene therapy for various cancers. The uracil phosphoribosyltransferase (UPRT) gene, which is absent from mammalian cells, directly converts 5-fluorouracil (5-FU) to 5-fluorouridine 5'-monophosphate. We evaluated whether the coexpression of CD and UPRT genes could generate a synergistic antitumor effect on experimental brain tumors. In vitro study showed that 9L cells, transduced with the UPRT gene by an adenovirus, were 16 times more sensitive to 5-FU, and CD + UPRT-transduced cells were 6,000 times more sensitive to 5-FC than parent cells, indicating that the acquisition of CD and UPRT further increased the 5-FC sensitivity of 9L cells compared with cells transduced with CD alone. In a rat brain tumor model, decreased amounts of CD and UPRT vectors were inoculated into the tumors to detect any additional effect of UPRT. CD and UPRT coexpression followed by 5-FC administration showed an antitumor effect as detected by sequential magnetic resonance imaging. This therapy significantly prolonged animal survival. These results suggest that 5-FC/CD + UPRT gene therapy can enhance the antitumor effect of 5-FC/CD gene therapy. Consequently, this approach might be a more feasible modality for the treatment of malignant brain tumors.
Asunto(s)
Adenoviridae/genética , Neoplasias Encefálicas/terapia , Flucitosina/uso terapéutico , Terapia Genética , Nucleósido Desaminasas/genética , Pentosiltransferasa/genética , Animales , Citosina Desaminasa , Técnicas de Transferencia de Gen , Vectores Genéticos/efectos adversos , Imagen por Resonancia Magnética , Ratas , Recombinación Genética , Células Tumorales CultivadasRESUMEN
Intratumoral grafting of genetically engineered cells that produce interleukin-4 (IL-4) has been shown to produce tumor regression as well as prolong survival of mice harboring intracerebral gliomas. We sought to determine whether retroviral-mediated gene delivery into tumor cells in situ resulted in enhanced tumor regression by IL-4. Two mouse fibroblast lines were obtained: they both secreted similar levels of IL-4 but one produced a retrovirus vector bearing the IL-4 gene (CRE-MFG-IL-4 cells), whereas the other did not (NIH3T3-IL-4 cells). In mixed transplantation assays in the subcutaneous flanks of athymic mice, CRE-MFG, IL-4 cells were more effective than NIH3T3-IL-4 cells in inhibiting the growth of rat C6 glioma cells (p < 0.005, ANOVA). Subcutaneous tumors injected with fibroblasts that produced a control retrovirus vector without producing IL-4 (CRE-MFG-LacZ cells) did not inhibit subcutaneous tumor growth. An intracranial assay was used to evaluate survival of athymic mice harboring intracranial gliomas. Three days after implanting rat C6 glioma cells into the right frontal lobes of athymic mice, NIH3T3-IL-4 cells (n = 10) or CRE-MFG-IL-4 cells (n = 10) were stereotactically inoculated into the tumor bed. The average survival of mice treated with CRE-MFG-IL-4 cells was 38 days (+/- 2.4, SE), whereas that of mice treated with NIH3T3-IL-4 cells was 31 days (+/- 0.8, SE) (p < 0.005, ANOVA; p < 0.001, log-rank analysis).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Células 3T3/trasplante , Neoplasias Encefálicas/terapia , Terapia Genética , Glioma/terapia , Factores Inmunológicos/uso terapéutico , Interleucina-4/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Células 3T3/metabolismo , Células 3T3/virología , Animales , Neoplasias Encefálicas/patología , Eosinofilia/etiología , Lóbulo Frontal , Vectores Genéticos/genética , Vectores Genéticos/fisiología , Glioma/patología , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/genética , Factores Inmunológicos/metabolismo , Inyecciones Intralesiones , Interleucina-4/administración & dosificación , Interleucina-4/genética , Interleucina-4/metabolismo , Ratones , Ratones Desnudos , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Técnicas Estereotáxicas , Replicación ViralRESUMEN
Most malignant tumors of the central nervous system do not respond well to chemotherapy. The anticancer drug cyclophosphamide (CPA) is largely ineffective against these neoplasms as its conversion to DNA-alkylating, cytotoxic metabolites is restricted primarily to the liver and these metabolites do not readily cross the blood-brain barrier. Here, we show that brain tumor cells can be sensitized to the cytotoxic effects of CPA, both in culture and in vivo, by introduction of the hepatic enzyme responsible for the activation of CPA, cytochrome P450 2B1. Stable transfection of rat C6 glioma cells with the P450 2B1 gene rendered the cultured tumor cells sensitive to CPA. Further, C6 cells bearing this gene were more sensitive than parental cells to the cytotoxic action of CPA when grown subcutaneously in the flanks of athymic mice. Murine fibroblasts producing a retrovirus vector encoding P450 2B1 and expressing this enzyme were then prepared and grafted into the brains of athymic mice seeded with rat C6 gliomas. Intrathecal administration of CPA prevented the development of meningeal neoplasia and led to partial regression of the parenchymal tumor mass. By contrast, C6 glioma-bearing mice receiving fibroblasts expressing the Escherichia coli lacZ gene and CPA exhibited extensive meningeal tumors and parenchymal solid brain tumors. The in situ activation of CPA by cytochrome P450 2B1 provides a novel approach not only for brain tumor gene therapy, but also for negative, drug-conditional selection of other defined cell populations.
Asunto(s)
Hidrocarburo de Aril Hidroxilasas , Neoplasias Encefálicas/terapia , Sistema Enzimático del Citocromo P-450/genética , Terapia Genética , Glioma/terapia , Neoplasias Meníngeas/terapia , Esteroide Hidroxilasas/genética , Animales , Biotransformación , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/genética , Células Cultivadas , Terapia Combinada , Ciclofosfamida/farmacocinética , Ciclofosfamida/uso terapéutico , Sistema Enzimático del Citocromo P-450/metabolismo , Resistencia a Medicamentos , Escherichia coli , Fibroblastos/trasplante , Glioma/tratamiento farmacológico , Glioma/genética , Operón Lac , Neoplasias Meníngeas/tratamiento farmacológico , Neoplasias Meníngeas/genética , Ratones , Ratones Desnudos , Ratas , Esteroide Hidroxilasas/metabolismo , Transfección , Células Tumorales CultivadasRESUMEN
p16 is involved in a cell-cycle regulatory cascade that includes cyclin-dependent kinase 4 (cdk4), cyclin D1 and pRb. Alterations of each of these components have been described in primary human glioblastoma multiforme (GBM) or GBM cell lines, and alterations of the individual components of this pathway appear inversely correlated with one another. While this suggests that disruption of any individual component has similar oncogenic effects, homozygous deletions of the CDKN2/p16 gene are the most common genetic alteration. We investigated the relationship between homozygous CDKN2/ p16 deletions and cellular proliferation in 50 primary astrocytomas (2 WHO grade I pilocytic astrocytoma, 15 grade II astrocytomas, 20 grade III anaplastic astrocytomas and 13 grade IV GBMs). Using a comparative multiplex PCR assay, homozygous deletions of the CDKN2/p16 gene were detected in 5 anaplastic astrocytomas (25%) and 6 GBMs (46%), but in none of the lower-grade tumors. Ki-67 immunohistochemistry was used to assess the number of proliferating cells in the same samples used for molecular genetic analysis. In both anaplastic astrocytomas and GBMs, Ki-67 proliferation indices were significantly higher in tumors with CDKN2/p16 deletions (20%) than in those without deletions (10%; p = 0.0001). These results suggest that homozygous CDKN2/p16 deletions in high-grade astrocytomas may have a more deleterious effect on cell cycle control than the other aberrations in the p16-cdk4-cyclin D1-pRb pathway, and may provide one explanation for why homozygous CDKN2/p16 deletions are more common genetic events in high-grade astrocytomas than RB mutations or CDK4 amplification.
Asunto(s)
Astrocitoma/genética , Neoplasias Encefálicas/genética , Proteínas Portadoras/genética , Eliminación de Gen , Genes Supresores de Tumor/genética , Antígeno Ki-67/genética , Adulto , Anciano , Astrocitoma/química , Neoplasias Encefálicas/química , Ciclo Celular/genética , División Celular/genética , Niño , Preescolar , Inhibidor p16 de la Quinasa Dependiente de Ciclina , ADN de Neoplasias/análisis , Femenino , Homocigoto , Humanos , Inmunohistoquímica , Antígeno Ki-67/análisis , Masculino , Persona de Mediana Edad , VolumetríaRESUMEN
BACKGROUND AND PURPOSE: Poly(ADP-ribose) polymerase (PARP) is important in modulating inflammation, which has been implicated in cerebral vasospasm after subarachnoid hemorrhage (SAH). We investigated the role of PARP in vasospasm using 3-aminobenzamide (3-AB), a PARP inhibitor, in a rabbit model. METHODS: Twenty-four New Zealand White rabbits were divided into 4 groups: (1) no treatment (control group, n=6); (2) blood injection without pretreatment (SAH-only group, n=6); (3) blood injection with pretreatment by vehicle (SAH+vehicle group, n=6); and (4) blood injection with pretreatment by 3-AB (SAH+3-AB group, n=6). We used the single-hemorrhage model of SAH, injecting autologous arterial blood into the cisterna magna. Angiography was performed before (baseline) and after (day 2) SAH, and the diameter of the basilar artery (BA) was measured. Animals were euthanatized after the second angiogram. After perfusion and fixation, the brains were cut into sections for hematoxylin and eosin and immunohistochemical staining for poly(ADP-ribosyl)ation. RESULTS: In the control group, there were no differences in the BA lumen caliber between baseline and day 2 (96.8+/-10.4%). Cerebral vasospasm in the SAH+3-AB group (88.2+/-6. 2%) was remarkably attenuated in comparison with that in the SAH-only group (64.9+/-8.0%) and the SAH+vehicle group (65.6+/-10. 8%). The BA in the SAH+3-AB group showed less corrugation of the tunica elastica interna than that in the SAH-only and SAH+vehicle groups. Staining for poly(ADP-ribosyl)ation was markedly inhibited in smooth muscle and adventitial cells of the BA in the SAH+3-AB group compared with other groups. CONCLUSIONS: Inhibiting ADP-ribosylation attenuates cerebral vasospasm after SAH in rabbits, and PARP activation may play an important role in the development of cerebral vasospasm.
Asunto(s)
Inhibidores de Poli(ADP-Ribosa) Polimerasas , Hemorragia Subaracnoidea/complicaciones , Vasoespasmo Intracraneal/enzimología , Animales , Arteria Basilar/diagnóstico por imagen , Arteria Basilar/efectos de los fármacos , Arteria Basilar/enzimología , Arteria Basilar/patología , Benzamidas/administración & dosificación , Angiografía Cerebral , Modelos Animales de Enfermedad , Endotelio Vascular/enzimología , Endotelio Vascular/patología , Inhibidores Enzimáticos/administración & dosificación , Inmunohistoquímica , Inyecciones , Masculino , Músculo Liso Vascular/enzimología , Músculo Liso Vascular/patología , Fármacos Neuroprotectores/administración & dosificación , Poli(ADP-Ribosa) Polimerasas/metabolismo , Conejos , Hemorragia Subaracnoidea/diagnóstico por imagen , Hemorragia Subaracnoidea/patología , Vasoespasmo Intracraneal/diagnóstico por imagen , Vasoespasmo Intracraneal/tratamiento farmacológico , Vasoespasmo Intracraneal/etiologíaRESUMEN
The genes encoding erabutoxin (short chain neurotoxin) isoforms (Ea, Eb, and Ec), LsIII (long chain neurotoxin) and a novel long chain neurotoxin pseudogene were cloned from a Laticauda semifasciata genomic library. Short and long chain neurotoxin genes were also cloned from the genome of Laticauda laticaudata, a closely related species of L. semifasciata, by PCR. A putative matrix attached region (MAR) sequence was found in the intron I of the LsIII gene. Comparative analysis of 11 structurally relevant snake toxin genes (three-finger-structure toxins) revealed the molecular evolution of these toxins. Three-finger-structure toxin genes diverged from a common ancestor through two types of evolutionary pathways (long and short types), early in the course of evolution. At a later stage of evolution in each gene, the accumulation of mutations in the exons, especially exon II, by accelerated evolution may have caused the increased diversification in their functions. It was also revealed that the putative MAR sequence found in the LsIII gene was integrated into the gene after the species-level divergence.
Asunto(s)
Elapidae/genética , Erabutoxinas/genética , Evolución Molecular , Intrones/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Clonación Molecular , ADN/química , ADN/genética , Variación Genética , Datos de Secuencia Molecular , Neurotoxinas/genética , Alineación de Secuencia , Análisis de Secuencia de ADN , Homología de Secuencia de Aminoácido , Homología de Secuencia de Ácido NucleicoRESUMEN
A cDNA encoding achacin, an antimicrobial glycoprotein from the body surface mucus of giant African snail Achacina fulica Férussac, was expressed in a methylotrophic yeast, Pichia pastoris, and recombinant achacin (rAch) was secreted in yeast minimal medium in a polyglycosylated form with 80 kDa. Carbohydrate analysis revealed that the glycosylated moiety of rAch was composed of 50 mol mannose and 2 mol N-acetylglucosamine residues. Antimicrobial activity using Escherichia coli and Staphylococcus aureus showed that the rAch had a behavior similar to its native counterpart. The rAch showed so wide an antimicrobial spectrum that 0.1 mg/ml rAch inhibited the growth of Pseudomonas fluorescens, Staphylococcus epidermidis, and Streptococcus faecalis in addition to E. coli and S. aureus, whereas it did not appreciably affect the growth of Proteus mirabilis, Bacillus cereus and Micrococcus luteus. The rAch was also effective in preventing growth of Vibrio anguillarum and Vibrio parahaemolyticus. The results suggested that the rAch had great potential of using as an antimicrobial agent.
Asunto(s)
Antiinfecciosos/farmacología , Glicoproteínas/farmacología , Neuropéptidos/farmacología , Animales , Expresión Génica , Glicoproteínas/genética , Neuropéptidos/genética , Pichia , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/farmacología , CaracolesRESUMEN
Genes that encode enzymes that convert inactive "prodrugs" into anticancer metabolites may be therapeutically useful against brain tumors. Unlike other genes tested to date in brain tumor models, the Escherichia coli gpt gene is unique in that it not only sensitizes cells to the prodrug 6-thioxanthine (6TX) but also encodes resistance to a different regimen (mycophenolic acid, xanthine, and hypoxanthine), thus providing a means to select for gpt-positive cells. In the present study, rat C6 glioma cells were infected with a retrovirus vector that transduces this gene. A clonal line (C6GPT-7) was derived that exhibited significant 6TX susceptibility in vitro with an ID50 of 2.5 mumol/L, whereas 50% growth inhibition of parental C6 cells was not achieved at concentrations tested (up to 50 mumol/L). This line also exhibited significant sensitivity to 6-thioguanine (6TG), with an ID50 of 0.05 mumol/L, whereas 50% growth inhibition of parental C6 cells was achieved at 0.5 mumol/L. In a "bystander" assay, C6GPT-7 tumor cells efficiently transferred 6TX sensitivity to C6 cells at ratios as low as 1:9 (C6GPT-7:C6). This in vitro bystander effect was abrogated when C6GPT-7 and C6 cells were separated by a microporous membrane, suggesting that it was not mediated by highly diffusible metabolites. In vivo both 6TX and 6TG significantly inhibited the growth of subcutaneously transplanted C6GPT-7 cells but not that of C6 cells in athymic mice. In an intracerebral model, both 6TX and 6TG exhibited significant antiproliferative effects against tumors formed by C6GPT-7 cells. These findings provide a basis for exploring further gene therapy strategies based on in vivo transfer of the E coli gpt gene to provide chemosensitivity against 6TX and 6TG.
Asunto(s)
Antimetabolitos Antineoplásicos/toxicidad , Terapia Genética/métodos , Glioma/patología , Hipoxantina Fosforribosiltransferasa/biosíntesis , Tioguanina/toxicidad , Transfección/métodos , Xantinas/toxicidad , Animales , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Escherichia coli/enzimología , Escherichia coli/genética , Glioma/tratamiento farmacológico , Hipoxantina Fosforribosiltransferasa/genética , Hipoxantina Fosforribosiltransferasa/metabolismo , Ratones , Ratones Desnudos , Ratas , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/metabolismo , Factores de Tiempo , Trasplante HeterólogoRESUMEN
We evaluated the therapeutic efficacy and neurotoxicity of adenovirus-mediated transduction of the cytosine deaminase (CD) gene and 5-fluorocytosine (5-FC) for experimental malignant brain tumors. The 5-FC sensitivity in 9 L cells infected by an adenovirus vector expressing CD (AdexCACD) was increased 1700-fold compared with control cells. Rats bearing 9 L brain tumors were treated with an intratumoral injection of AdexCACD followed by intraperitoneal administration of 5-FC. The rats demonstrated remarkable inhibition of tumor growth by magnetic resonance imaging, and 7 of 10 rats survived for >90 days. To evaluate the potential side-effects of the 5-FC/CD gene therapy, rats were treated with an intracerebral injection of AdexCACD into the right basal ganglia and with 5-FC. The magnetic resonance imaging showed a highly enhanced area on the gadollinium-enhanced T1-weighted image at 18 days postinjection. Pathologically, this corresponded to an area of necrosis with surrounding apoptotic cells. In addition, there was demyelination and gliosis with enlargement of the lateral ventricles. These results suggest that the 5-FC/CD gene therapy may provide an anticancer effect for malignant brain tumors in humans, but also show that there are neurotoxic effects on normal brain tissue.